Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Retained Earnings came in at -$814.2 million in Q1 2026, down 103.99% YoY from $20.4 billion in Q1 2025, and down 18.21% on a QoQ basis from -$688.8 million in Q4 2025.
Analysis
Minerva Neurosciences (NERV) Retained Earnings (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Retained Earnings data on file, last reported at -$814.2 million in Q1 2026.
- Quarterly Retained Earnings fell 103.99% year-over-year to -$814.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$814.2 million (down 103.99% YoY) and the FY2025 annual result came in at -$688.8 million, down 74.21% from the prior year.
- Retained Earnings slipped to -$814.2 million in Q1 2026, from -$688.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$344.5 million in Q1 2022 to a low of -$814.2 million in Q1 2026.
- A 5-year average of -$428.1 million and a median of -$395.4 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings grew 2.71% — and 2026, when it slumped 103.99%.
- Tracing NERV's Retained Earnings over 5 years: stood at -$366.8 million in 2022, then fell by 8.18% to -$396.8 million in 2023, then increased by 0.36% to -$395.4 million in 2024, then plunged by 74.21% to -$688.8 million in 2025, then dropped by 18.21% to -$814.2 million in 2026.
- The last three Retained Earnings figures came in at -$814.2 million (Q1 2026), -$688.8 million (Q4 2025), and -$405.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | -796.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -796.74 Mn |
| Mar 31, 2026 | -814.20 Mn |
| Dec 31, 2025 | -688.80 Mn |
| Sep 30, 2025 | -405.13 Mn |
| Jun 30, 2025 | -402.40 Mn |
| Mar 31, 2025 | -399.13 Mn |
| Dec 31, 2024 | -395.38 Mn |
| Sep 30, 2024 | -391.10 Mn |
| Jun 30, 2024 | -413.62 Mn |
| Mar 31, 2024 | -405.40 Mn |
| Dec 31, 2023 | -396.82 Mn |
| Sep 30, 2023 | -387.80 Mn |
| Jun 30, 2023 | -380.00 Mn |
| Mar 31, 2023 | -373.80 Mn |
| Dec 31, 2022 | -366.81 Mn |
| Sep 30, 2022 | -360.10 Mn |
| Jun 30, 2022 | -353.20 Mn |
| Mar 31, 2022 | -344.47 Mn |
| Dec 31, 2021 | -334.70 Mn |
| Sep 30, 2021 | -313.40 Mn |